Takeda Pharmaceutical Company Limited Dividend History (TAK)

The global activated carbon fiber (ACF) market is expected to reach a value of USD 762.85 Million by 2031, driven by increasing demand for efficient filtration and purification solutions across various industries. Synthetic materials are dominating the market due to their enhanced adsorption capacity and durability, while the wastewater treatment segment is leading the market due to the growing need for effective pollution control.

The global blood plasma derivatives market is expected to grow from $48.3 billion in 2023 to $115.7 billion in 2033, driven by factors such as government initiatives, rising plasma collection centers, and innovative formulations. The market is segmented by type, application, and end-user, with immunoglobulin, immunodeficiency diseases, and hospitals being the largest segments, respectively.

HUTCHMED announces the launch of its cancer drug FRUZAQLA (fruquintinib) in Japan for the treatment of metastatic colorectal cancer, following approval by the Japanese Ministry of Health, Labour and Welfare. The launch marks a milestone in HUTCHMED's partnership with Takeda, which has the exclusive worldwide license to develop and commercialize fruquintinib outside of mainland China, Hong Kong and Macau.